Relaxin level in patients with atrial fibrillation and association with heart failure occurrence


Atrial fibrillation is the most common arrhythmia requiring medical treatment and has been associated with enhanced atrial fibrosis and heart failure.
Relaxin, an antifibrosis and antiinflammatory peptide hormone, may be used to evaluate atrial fibrosis and is associated with heart failure occurrence in atrial fibrillation.

A study has aimed to clarify the clinical significance of relaxin level in patients with atrial fibrillation.

Researchers measured circulating levels of relaxin and other fibrosis-related factors in 311 patients with sinus rhythm ( SR; n = 116 ) or atrial fibrillation ( n = 195 ).

All discharged patients with atrial fibrillation were followed up for the occurrence of heart failure for a mean of 6 months.

Circulating levels of relaxin were significantly different in patients with atrial fibrillation as compared with sinus rhythm ( P  less than 0.001), and in the subgroup analysis of atrial fibrillation.

Relaxin level was correlated with left atrial diameter ( LAD; R = 0.358, P  less than  0.001 ).

Among followed-up patients with atrial fibrillation, on Kaplan-Meier curve analysis, patients with the third relaxin tertile ( T3 ) had a significantly higher heart failure rate than those with the 1st tertile ( T1 ) ( P = 0.002 ) and the cut-off value was 294.8 ng/L ( area under the ROC curve [ AUC ] = 0.723 ).

On multivariable analysis, heart failure occurrence with atrial fibrillation was associated with increased tertile of serum relaxin level ( odds ratio [ OR ] 2.659; confidence interval [ 95% CI ] 1.434-4.930; P = 0.002 ).

Relaxin is associated with fibrosis-related biomarkers and significantly elevated in atrial fibrillation.
Relaxin was related to the heart failure occurrence in patients with atrial fibrillation. ( Xagena )

Zhou H et al, Medicine ( Baltimore ) 2016; 95 ( 21 ):e3664

XagenaMedicine_2016



Indietro

Altri articoli

The FDA ( U.S. Food and Drug Administration ) has approved Darzalex Faspro ( Daratumumab and Hyaluronidase-fihj ), a...


The Pfizer-BioNTech COVID-19 vaccine contains a nucleoside-modified messenger RNA ( modRNA ) encoding the viral spike glycoprotein ( S ) of...


COVID-19 can have fatal consequences for people with underlying cardiovascular disease and cause cardiac injury even in patients without underlying...


Atrial fibrillation is the most frequent sustained arrhythmia. Atrial fibrillation often recurs after restoration of normal sinus rhythm. Antiarrhythmic drugs...


Implantable cardioverter-defibrillator ( ICD ) use is associated with reduced short- and long-term mortality in patients with heart failure. Patients with...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Brukinsa ( Zanubrutinib ) capsules for...


The European Commission has approved a label update for the use of once-daily Relvar Ellipta ( Fluticasone furoate / Vilanterol,...


In acute coronary syndrome ( ACS ), potassium imbalance at admission has been associated with in-hospital arrhythmias, cardiac arrest, and...


Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...


As the Zika virus continues to spread globally, new evidence has emerged about the virus's potentially detrimental effects on the...